The abstract is read at the publisher; the summary is JClub's.
In diffuse large B-cell lymphoma cells, inhibiting PIM kinases globally reduces histone H3 serine 10 phosphorylation and active histone marks, impairing RNA polymerase II elongation and transcription.
- Why it matters: DLBCL often relapses or becomes refractory after chemoimmunotherapy, and the molecular links between PIM kinase activity, transcriptional control, RNA processing, and genome stability are unclear.
- What they did: The study used genetic or pharmacological PIM family inhibition, then integrated epigenomic and transcriptomic profiling to assess histone marks, RNA polymerase II elongation, and RNA metabolism networks, alongside PIM1 proximity proteomics and co-immunoprecipitation.
- The result: PIM inhibition induces widespread transcriptional repression, extensive alternative mRNA splicing abnormalities, R-loop accumulation, and DNA damage checkpoint responses, and it synergizes with DNA-damaging chemotherapy and DNA damage response inhibitors in preliminary in vitro drug combinations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.